← Back to Search

Only 4 spots left

~4 spots leftby Nov 2025

Nivolumab + Radiation + Bevacizumab for Glioblastoma

Palo Alto (17 mi)

Overseen byChristian Grommes, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.

Eligibility Criteria

Adults with confirmed grade IV glioblastoma, IDH wildtype, MGMT hypermethylation, who've had surgery and chemo with temozolomide followed by radiation. They must show signs of recurrence but have a relatively small tumor (≤5cm), good performance status, and normal organ function. Excluded are those with multiple recurrences, certain heart conditions or infections, active autoimmune diseases requiring recent treatment, pregnancy/breastfeeding intentions within trial period, MRI incompatibility or prior treatments conflicting with the study drugs.

Inclusion Criteria

I have been treated with radiation and temozolomide.

My bone marrow is working well.

I am mostly able to care for myself and carry out daily activities.

I am 18 years old or older.

My tumor is 5 cm or smaller and shows up on contrast imaging.

My tumor biopsy shows MGMT hypermethylation.

My glioblastoma is grade IV and IDH wildtype.

I have had the largest possible surgery to remove my tumor.

I have had one round of radiation therapy before.

My cancer has come back, as shown by tests or scans.

Exclusion Criteria

I have not had a heart attack or unstable chest pain in the last year.

My tumor is larger than 5 cm and shows up on contrast imaging.

I have a wound, ulcer, or bone fracture that hasn’t healed.

I have been treated with bevacizumab before.

I have a history of lung inflammation not caused by an infection.

I haven't had a peptic ulcer, abdominal issues like fistula, perforation, or abscess in the last 6 months.

I have moderate to severe heart failure.

My high blood pressure is not controlled by medication.

My cancer recurrence is located below the tentorium in my brain.

I am not allergic to nivolumab, bevacizumab, or their ingredients.

I have an active tuberculosis infection.

My brain tumor has an IDH mutation.

I have been treated with immune checkpoint inhibitors.

I am currently on medication for an infection.

I haven't needed systemic treatment for an autoimmune disease in the last 2 years.

I need high doses of steroids daily to manage my condition.

My cancer has returned more than once after initial treatment.

I have been diagnosed with an immunodeficiency condition, such as HIV or AIDS.

Treatment Details

The trial tests if adding nivolumab to standard re-irradiation therapy and bevacizumab improves outcomes for recurrent glioblastoma patients. It's exploring whether this combination can better control tumor growth compared to current methods.

2Treatment groups

Experimental Treatment

Group I: Recurrent Glioblastoma, SurgeryExperimental Treatment4 Interventions

The second cohort is for patients with recurrent GBM who are undergoing surgery as part of their treatment.

Group II: Recurrent Glioblastoma, No SurgeryExperimental Treatment3 Interventions

One cohort is for patients with recurrent GBM who are not undergoing surgical debulking as part of their treatment plan

Bevacizumab is already approved in European Union, United States, Japan, Canada for the following indications:

🇪🇺 Approved in European Union as Avastin for: